ARQT — Arcutis Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $1.10bn
- $1.03bn
- $59.61m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -42 | -136 | -206 | -311 | -262 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 0.597 | 8.39 | 27.7 | 63 | 37.1 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1.5 | 14.1 | 3.62 | -10.2 | -23.5 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Cash from Operating Activities | -42.8 | -113 | -175 | -258 | -247 |
Capital Expenditures | -0.295 | -0.321 | -0.995 | -23.3 | -0.428 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -26 | -182 | -75 | -63.9 | 181 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -26.3 | -182 | -76 | -87.2 | 180 |
Financing Cash Flow Items | -1.4 | 0 | -1.64 | -2.19 | 0 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 93.1 | 298 | 282 | 302 | 101 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 23.9 | 3.29 | 31.4 | -43.1 | 34.4 |